Statistics from Altmetric.com
Preusser M, De Mattos-Arruda L, Thill M, et al. CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. ESMO Open 2018;3:e000368. doi: 10.1136/esmoopen-2018-000368.
This article has been corrected since its first publication.
Pages 5: The text on abemaciclib in the MONARCH 1 study has been corrected to:
Abemaciclib led to an ORR of 19.7%, CBR of 42.4% and median PFS of 6.0 months. The most common AEs all grades were diarrhea (90.2%), fatigue (65.2%), nausea (64.4%), decreased appetite (45.5%), and abdominal pain (38.6%).
Page 6. The first sentence on adjuvant setting has been corrected to:
In addition to the neoadjuvant setting, two prospective randomised phase III trials evaluating the role of the three different CDK4/6 inhibitors as adjuvant therapy when added to standard ET are currently ongoing (palbociclib: PALLAS, NCT02513394; abemaciclib: MonarchE, NCT03155997).
Page 8. The first and last author’s competing interests have been updated:
MP: Honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Merck Sharp & Dome.
CZ: Honoraria from Roche, Novartis, BMS, MSD, Imugene, Ariad, Pfizer, Merrimack, Merck KGaA, Fibrogen, AstraZeneca, Tesaro, Gilead, Servier, Shire.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.